PRMT5 and B-cell non-Hodgkin lymphoma: JNJ-64619178, a SAM-competitive inhibitor, binds to SAM- and the protein substrate binding domain of PRMT5 is being tested in a phase I clinical trial (NCT03573310) against B cell non-Hodgkin lymphoma and solid tumors.